Spectrum’s Zevalin Still Living In Rituxan’s Shadow, FDA Advertising Letter Shows
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA citations of Rituxan comparisons in a promotion for Zevalin throw added salt on old wounds for drug that has taken backseat to Rituxan’s blockbuster story.
You may also be interested in...
Promotions For Black-Box Drugs Aren’t Specific Enforcement Targets, FDA Says
FDA advertising enforcement does not preference black-box drugs despite risk-based approach prioritizing products with significant risks; nor are drugs with small patient populations exempt from risk-based approach.
Cancer Drug Zevalin May Finally Thrive Under Spectrum
The small oncology company may be able to succeed with the non-Hodgkin lymphoma drug where others have failed.
FDA’s Authority Looks Safe From Judicial Interference Following Supreme Court Abortion Pill Arguments
The agency's and the pharma industry’s worst fears – that a potential ruling in the mifepristone case might usurp the FDA’s scientific authority and throw the stability of the US drug approval process into question – seem unlikely to materialize as the majority of the Supreme Court justices signal the Alliance for Hippocratic Medicine lacks standing to sue.